Literature DB >> 34155393

KTE-X19 efficacious in adults with B-ALL.

David Killock1.   

Abstract

Year:  2021        PMID： 34155393     DOI： 10.1038/s41571-021-00537-6

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.

Authors:  Bijal D Shah; Armin Ghobadi; Olalekan O Oluwole; Aaron C Logan; Nicolas Boissel; Ryan D Cassaday; Thibaut Leguay; Michael R Bishop; Max S Topp; Dimitrios Tzachanis; Kristen M O'Dwyer; Martha L Arellano; Yi Lin; Maria R Baer; Gary J Schiller; Jae H Park; Marion Subklewe; Mehrdad Abedi; Monique C Minnema; William G Wierda; Daniel J DeAngelo; Patrick Stiff; Deepa Jeyakumar; Chaoling Feng; Jinghui Dong; Tong Shen; Francesca Milletti; John M Rossi; Remus Vezan; Behzad Kharabi Masouleh; Roch Houot
Journal:  Lancet       Date:  2021-06-03       Impact factor: 79.321
  1 in total
  2 in total

Review 1.  Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives.

Authors:  Meng Lv; Yan Liu; Wei Liu; Yabing Xing; Shengnan Zhang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

Review 2.  Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.

Authors:  Ali Keshavarz; Ali Salehi; Setareh Khosravi; Yasaman Shariati; Navid Nasrabadi; Mohammad Saeed Kahrizi; Sairan Maghsoodi; Amirhossein Mardi; Ramyar Azizi; Samira Jamali; Farnoush Fotovat
Journal:  Stem Cell Res Ther       Date:  2022-09-24       Impact factor: 8.079
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.